Main Menu

Corcept Therapeutics Incorporated

(NASDAQ CM: CORT)

Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Corcept Therapeutics Incorporated ("Corcept") on behalf of stockholders.  A class action complaint has been filed against Corcept, which alleges that defendants made materially false and/or misleading statements, and failed to disclose material adverse facts about Corcept's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (i) Corcept improperly paid doctors to promote its drug Korlym; (ii) Corcept aggressively promoted Korlym for off-label uses; (iii) Corcept's sole specialty pharmacy was a related party; (iv) Corcept artificially inflated its revenue and sales using illicit sales practices through a related party; (v) such practices are reasonably likely to lead to regulatory scrutiny; and (vi) thus, defendants' positive statements about Corcept's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 09/29/2022


* Indicates a required field.

Back to Page